Cytori Cell Research Institute, Inc. (JP:3750)

:3750

3750

Cytori Cell Research Institute, Inc.

RESEARCH TOOLSreports

Want to see JP:3750 full AI Analyst Report?

Cytori Cell Research Institute, Inc. (3750) Price & Analysis

1 Followers

3750 Stock Chart & Stats

¥840.00

-¥5.00(-0.59%)

At close: Jan 08 4:00 PM EST

¥840.00

-¥5.00(-0.59%)

Day’s Range― - ―

52-Week Range¥710.00 - ¥990.00

Previous CloseN/A

Volume9.00K

Average Volume (3M)5.90K

Market Cap

¥7.13B

Enterprise Value¥7.02B

Total Cash (Recent Filing)¥369.76M

Total Debt (Recent Filing)¥0.00

Price to Earnings (P/E)―

Beta0.39

Next Earnings

Aug 12, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-204.72

Shares Outstanding8,929,419

10 Day Avg. Volume2,510

30 Day Avg. Volume5,903

Financial Highlights & Ratios

PEG Ratio0.22

Price to Book (P/B)329.97

Price to Sales (P/S)142.53

P/FCF Ratio-9.26

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Deleveraged Balance Sheet (zero Reported Debt)Zero reported debt in 2026 indicates a deleveraging event that reduces interest and covenant pressure, improving near-term financial flexibility. Over 2–6 months this lowers refinancing risk and gives management runway to restructure operations or seek non-debt funding, though equity remains small.

Gross Margin Returned To PositiveGross margin returning to ~19% in 2026 restores positive unit economics at the product level. This structural improvement suggests core operations can generate gross profit if volumes or pricing stabilize, enabling management to focus on reducing operating losses and improving sustainability over the medium term.

Reduced Absolute Cash Outflow Vs Prior YearOperating and free cash flow improved in absolute terms versus 2025 (OPCF -784.8M vs -987.0M), signaling slower cash burn. While still negative, a sustained trend of lower outflows would extend runway, reduce urgent financing needs, and allow more deliberate restructuring or business development actions over coming months.

Bears Say

Severe Revenue DeclineRevenue collapsed to 50.99M in 2026 from 122.20M in 2025 and 1.56B in 2024. This severe top-line erosion undermines scale, reduces pricing leverage and R&D funding, and increases per-unit fixed cost pressure, making durable recovery dependent on new revenue drivers or a successful strategic pivot.

Persistent Heavy Cash BurnOperating cash flow remains heavily negative (-784.8M in 2026 after -987.0M in 2025 and -1.15B in 2024). Persistent negative OCF forces reliance on external financing, limits the ability to reinvest in growth, increases dilution risk, and threatens solvency if the company cannot arrest the burn within several quarters.

Collapsed Equity / Thin Capital BufferEquity fell to 22.0M in 2026 from 2.79B in 2024 and 630.5M in 2025, removing a loss-absorbing buffer. With minimal shareholders' equity the company faces heightened solvency risk, weakened lender confidence, and severely constrained strategic options absent rapid operational improvement or fresh capital injections.

3750 FAQ

What was Cytori Cell Research Institute, Inc.’s price range in the past 12 months?

Cytori Cell Research Institute, Inc. lowest stock price was ¥710.00 and its highest was ¥990.00 in the past 12 months.

What is Cytori Cell Research Institute, Inc.’s market cap?

Cytori Cell Research Institute, Inc.’s market cap is ¥7.13B.

When is Cytori Cell Research Institute, Inc.’s upcoming earnings report date?

Cytori Cell Research Institute, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 60 days.

How were Cytori Cell Research Institute, Inc.’s earnings last quarter?

Cytori Cell Research Institute, Inc. released its earnings results on May 15, 2026. The company reported -¥8.96 earnings per share for the quarter, missing the consensus estimate of N/A by -¥8.96.

Is Cytori Cell Research Institute, Inc. overvalued?

According to Wall Street analysts Cytori Cell Research Institute, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Cytori Cell Research Institute, Inc. pay dividends?

Cytori Cell Research Institute, Inc. pays a Annually dividend of ¥10 which represents an annual dividend yield of N/A. See more information on Cytori Cell Research Institute, Inc. dividends here

What is Cytori Cell Research Institute, Inc.’s EPS estimate?

Cytori Cell Research Institute, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Cytori Cell Research Institute, Inc. have?

Cytori Cell Research Institute, Inc. has 8,929,419 shares outstanding.

What happened to Cytori Cell Research Institute, Inc.’s price movement after its last earnings report?

Cytori Cell Research Institute, Inc. reported an EPS of -¥8.96 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.124%.

Which hedge fund is a major shareholder of Cytori Cell Research Institute, Inc.?

Currently, no hedge funds are holding shares in JP:3750

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Cytori Cell Research Institute, Inc.

Operating from its Tokyo headquarters, Cytori Cell Research Institute, Inc., established in 2004 (originally FRACTALE Corporation), specializes in the comprehensive research, development, production, and distribution of medical devices related to cell therapy throughout Japan. The company offers various cell therapy kits and continuously advances cellular treatment technologies through ongoing research and development. Its active development pipeline includes ECCI-50, designed for the treatment of male stress urinary incontinence and hepatic cirrhosis, and Cyt-006, formulated to prevent postoperative adhesion after primary rectal cancer surgery. Additionally, Cytori conducts extensive clinical trials and investigations into cell-based therapies for a wide array of conditions and applications, such as the repair of anterior cruciate ligaments and bones, burn scar remediation, chronic wound healing, critical limb ischemia, treatment of anal and Crohn's disease fistulas, and erectile dysfunction. Beyond its primary biotechnological focus, the company also participates in the real estate sector, encompassing investment, ownership, development, leasing, and management of properties and hotels, as well as providing real estate brokerage services.